Antibiotic Awareness Week: Promoting patient safety through responsible practices

Nov. 2026Important Notices

Strengthening antibiotic and antifungal guidance can help combat resistance and improve patient outcomes.

The effectiveness of antibiotics and antifungals is essential to modern healthcare—from treating common infections and managing sepsis to supporting safe surgeries and cancer care. During U.S. Antibiotic Awareness Week (USAAW), observed Nov. 18 to 24, healthcare professionals have an opportunity to consider how clinical decision making, prescribing practices, and infection prevention can help preserve the effectiveness of these important therapies.

Antibiotic stewardship is not simply about prescribing fewer medications. It is about using the right treatment, for the right patient, at the right dose, by the right route, and for the right duration. When a serious bacterial infection is suspected, timely and appropriate therapy remains critical and can save lives. As clinical, laboratory, culture, and other diagnostic information becomes available, clinicians should reassess the clinical scenario and determine whether treatment should be continued, narrowed, adjusted, or discontinued.

Distinguishing a bacterial from a viral illness is the first step. Antibiotics are not effective against influenza, the common cold, or most acute bronchitis. In addition, many sinus and some ear infections can clear up their own. Clinicians should base prescribing decisions on clinical findings, appropriate diagnostic testing, and current guidelines rather than the assumption that every symptomatic patient needs an antibiotic.

Proper antibiotic stewardship also requires attention to prevention of potential harms. Antibiotic exposure can cause adverse reactions while increasing selective pressure for microbial resistance. Reviewing reported penicillin allergies can improve prescribing options—the Centers for Disease Control and Prevention (CDC) notes that approximately 10 percent of U.S. patients report a penicillin allergy, but fewer than 1 percent are truly allergic. Risk-based evaluation can prevent unnecessary reliance on broader-spectrum alternatives.

Antifungal stewardship matters just as much. Inappropriate treatment, dosing, or prophylaxis can speed the development of resistance. Whenever possible, confirm a fungal diagnosis before starting therapy, and document the indication, dose, and planned duration. When treatment fails, consider susceptibility testing, particularly if a resistant organism is suspected.

Drug selection and monitoring are equally important. Some antifungals carry risks of liver toxicity and drug interactions, and amphotericin B can damage the kidneys. Therapeutic drug monitoring can help optimize triazole therapy (such as voriconazole, posaconazole, and itraconazole), which is often used in immunocompromised patients. For suspected superficial fungal infections, avoid a routine combination of antifungal-corticosteroid products, which may worsen the condition.

The CDC's guidance on antibiotics and antifungals requires diligence at all levels of care. It stresses the importance of leadership support, accountability, pharmacy expertise, actionable interventions, tracking, reporting, and education. In both inpatient and outpatient settings, everyone involved in care contributes to responsible antimicrobial use. This means balancing prompt, effective treatment with ongoing reassessment. Every necessary prescription—and every unnecessary prescription avoided—strengthens patient safety and preserves options for patients who will need antibiotics and antifungal medications in the future.

Sources

cdc.gov/antibiotic-use/index.html 

cdc.gov/antimicrobial-resistance/communication-resources/usaaw.html

cdc.gov/antibiotic-use/about/index.html

cdc.gov/fungal/treatment/index.html

cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html


Recent Announcements

Access member care plans in UPMC Health Plan Tapestry Link

Starting Dec. 1, 2026, providers will be able to access SNP care plans within UPMC Health Plan Tapestry Link. Care plans are visible on a member’s chart in multiple locations:
Nov. 2026Important Notices

UPMC Health Plan Tapestry Link resources available

UPMC Health Plan Tapestry Link will launch on Tuesday, Dec. 1, 2026. To help ease your transition to the new platform, we have developed the following resources:
Nov. 2026Important Notices

Changes to inpatient denial and OBS claim billing

We will soon transition to the Epic® platform. This change will align our claims processing with industry standards by adjudicating claims based on the level of care authorized. As this transition approaches, please keep the following areas in mind:
Nov. 2026